Your browser doesn't support javascript.
loading
A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications.
Earl, Julie; Calabuig-Fariñas, Silvia; Sarasquete, María Eugenia; Muinelo Romay, Laura; Lopez-Tarruella, Sara; Bellosillo Paricio, Beatriz; Rodríguez, Marta; Valencia Leoz, Karmele; Dueñas Porto, Marta; Tarazona, Noelia; Hernandez Losa, Javier; Toledo, Rodrigo Almeida.
Afiliação
  • Earl J; The Liquid Biopsy and Biomarker Working Module, the Biomedical Research Network in Cancer (CIBERONC); julie.earl@live.co.uk.
  • Calabuig-Fariñas S; The Liquid Biopsy and Biomarker Working Module, the Biomedical Research Network in Cancer (CIBERONC).
  • Sarasquete ME; The Liquid Biopsy and Biomarker Working Module, the Biomedical Research Network in Cancer (CIBERONC).
  • Muinelo Romay L; The Liquid Biopsy and Biomarker Working Module, the Biomedical Research Network in Cancer (CIBERONC).
  • Lopez-Tarruella S; The Liquid Biopsy and Biomarker Working Module, the Biomedical Research Network in Cancer (CIBERONC).
  • Bellosillo Paricio B; The Liquid Biopsy and Biomarker Working Module, the Biomedical Research Network in Cancer (CIBERONC).
  • Rodríguez M; The Liquid Biopsy and Biomarker Working Module, the Biomedical Research Network in Cancer (CIBERONC).
  • Valencia Leoz K; The Liquid Biopsy and Biomarker Working Module, the Biomedical Research Network in Cancer (CIBERONC).
  • Dueñas Porto M; The Liquid Biopsy and Biomarker Working Module, the Biomedical Research Network in Cancer (CIBERONC).
  • Tarazona N; The Liquid Biopsy and Biomarker Working Module, the Biomedical Research Network in Cancer (CIBERONC).
  • Hernandez Losa J; The Liquid Biopsy and Biomarker Working Module, the Biomedical Research Network in Cancer (CIBERONC).
  • Toledo RA; The Liquid Biopsy and Biomarker Working Module, the Biomedical Research Network in Cancer (CIBERONC); rtoledo@vhio.net.
J Vis Exp ; (187)2022 09 16.
Article em En | MEDLINE | ID: mdl-36190291
ABSTRACT
The term liquid biopsy (LB) refers to molecules such as proteins, DNA, RNA, cells, or extracellular vesicles in blood and other bodily fluids that originate from the primary and/or metastatic tumor. LB has emerged as a mainstay in translational research and has started to become part of clinical oncology practice, providing a minimally invasive alternative to solid biopsy. The LB allows real-time monitoring of a tumor via a minimally invasive sample extraction, such as blood. The applications include early cancer detection, patient follow-up for the detection of disease progression, assessment of minimal residual disease, and potential identification of molecular progression and mechanism of resistance. In order to achieve a reliable analysis of these samples that can be reported in the clinic, the preanalytical procedures should be carefully considered and strictly followed. Sample collection, quality, and storage are crucial steps that determine their usefulness in downstream applications. Here, we present standardized protocols from our liquid biopsy working module for collecting, processing, and storing plasma and serum samples for downstream liquid biopsy analysis based on circulating-free DNA. The protocols presented here require standard equipment and are sufficiently flexible to be applied in most laboratories focused on biological procedures.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ácidos Nucleicos Livres / Células Neoplásicas Circulantes Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: J Vis Exp Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ácidos Nucleicos Livres / Células Neoplásicas Circulantes Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: J Vis Exp Ano de publicação: 2022 Tipo de documento: Article